Geoffrey D. Miller

Geoffrey D. Miller

Auto-generated profile, based on publicly available information

Geoffrey D. Miller

Sports Medicine Research and Testing Laboratory South Jordan Utah USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2019 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
GMGeoffrey D. Miller
Geoffrey D. Miller
MTMasaru Teramoto
Masaru Teramoto
SSStacy J. Smeal
Stacy J. Smeal
DCDan Cushman
Dan Cushman
DEDaniel Eichner
Daniel Eichner


28 March 2022 in Drug Testing and Analysis
Verified
Journal Article
Closed access
JGJenna M. Goodrum
Jenna M. Goodrum
LLLaura A. Lewis
Laura A. Lewis
MFMatthew N. Fedoruk
Matthew N. Fedoruk
DEDaniel Eichner
Daniel Eichner
GMGeoffrey D. Miller
Geoffrey D. Miller

23 June 2020 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
VNVinod S. Nair
Vinod S. Nair
JHJacob Husk
Jacob Husk
GMGeoffrey D. Miller
Geoffrey D. Miller
PEPeter van Eenoo
Peter van Eenoo
ACAndre Crouch
Andre Crouch
DEDaniel Eichner
Daniel Eichner

22 July 2020 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
VNVinod S. Nair
Vinod S. Nair
CDChristine E. Doman
Christine E. Doman
MMMatthew S. Morrison
Matthew S. Morrison
GMGeoffrey D. Miller
Geoffrey D. Miller
JHJacob Husk
Jacob Husk
DEDaniel Eichner
Daniel Eichner

7 July 2021 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
FLFrancesco Loria
Francesco Loria
HCHolly D. Cox
Holly D. Cox
SVSven C. Voss
Sven C. Voss
ARAngela Rocca
Angela Rocca
GMGeoffrey D. Miller
Geoffrey D. Miller
NLNicolas Leuenberger
Nicolas Leuenberger
The hematological module of the Athlete Biological Passport (ABP) is used for indirect detection of blood manipulations; however, the use of this method to detect doping, such as with microdoses of recombinant human erythropoietin (rhEPO), is problematic. For this reason, the sensitivity of ABP must be enhanced by implementing novel biomarkers. Here, we show that 5'‐aminolevulinate synthase 2 (ALAS2) mRNAs are useful transcriptomic biomarkers to improve the indirect detection of rhEPO microdosing. Moreover, the sensitivity was sufficient to distinguish rhEPO administration from exposure to hypoxic conditions. Levels of mRNAs encoding carbonate anhydrase 1 (CA1) and solute carrier family 4 member 1 (SLC4A1) RNA, as well as the linear (L) and linear + circular (LC) forms of ALAS2 mRNA, were monitored for 16 days after rhEPO microdosing and during exposure to hypoxic conditions. ALAS2 mRNAs increased by 300% compared with the baseline values after rhEPO microdosing. Moreover, ALAS2 mRNAs were not significantly increased under hypoxic conditions. By contrast, CA1 mRNA was increased after both rhEPO microdosing and hypoxia, whereas SLC4A1 mRNA did not significantly increase under either condition. Furthermore, the analyses described here were performed using dried blood spots (DBSs), which provide advantages in terms of the sample collection, transport, and storage logistics. This study demonstrates that ALAS2 mRNA levels are sensitive and specific transcriptomic biomarkers for the detection of rhEPO microdosing using the hematological module of the ABP, and this method is compatible with the use of DBSs for anti‐doping analyses.